Wall Street brokerages expect that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post earnings per share (EPS) of ($0.29) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Inovio Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.24). Inovio Pharmaceuticals reported earnings per share of ($0.36) during the same quarter last year, which would suggest a positive year-over-year growth rate of 19.4%. The company is expected to report its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($1.03). For the next year, analysts expect that the firm will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.47) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). The business had revenue of $2.60 million for the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business’s revenue was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share.

INO has been the topic of a number of recent research reports. ValuEngine lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada initiated coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target on the stock. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, BidaskClub lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $19.16.

Hedge funds have recently modified their holdings of the business. Virginia Retirement Systems ET AL purchased a new position in Inovio Pharmaceuticals during the third quarter worth about $101,000. BlueCrest Capital Management Ltd purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $107,000. Neuberger Berman Group LLC purchased a new position in Inovio Pharmaceuticals during the third quarter worth about $115,000. Engineers Gate Manager LP purchased a new position in Inovio Pharmaceuticals during the third quarter worth about $117,000. Finally, Emerald Advisers Inc. PA raised its stake in Inovio Pharmaceuticals by 84.0% during the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 9,280 shares during the period. 32.12% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals (INO) traded down $0.01 on Thursday, reaching $4.46. 740,946 shares of the company were exchanged, compared to its average volume of 1,290,000. The firm has a market capitalization of $402.72, a price-to-earnings ratio of -3.78 and a beta of 2.74. Inovio Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $9.86.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/01/14/0-29-earnings-per-share-expected-for-inovio-pharmaceuticals-inc-ino-this-quarter.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.